Furthermore, the venetoclax-S63845 combination potentiated melanoma cell killing caused by the BRAFV600E inhibitor darafenib in BRAF-mutant melanoma cells (Supplementary Fig. S16). This evidence concerns the gene BRAF and melanoma.